Recombinant
RabMAb

Recombinant Anti-CD26 antibody [EPR5883(2)] (ab129060)

Overview

  • Product name

    Anti-CD26 antibody [EPR5883(2)]
    See all CD26 primary antibodies
  • Description

    Rabbit monoclonal [EPR5883(2)] to CD26
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: ICC/IF or IHC-P
  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Pig
  • Immunogen

    Synthetic peptide within Human CD26 aa 700 to the C-terminus (extracellular). The exact sequence is proprietary.
    (Peptide available as ab188121)

  • Positive control

    • WB: HUVEC, PC-3, U87-MG and Ramos cell lysates. Mouse and rat brain tissue lysates.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab129060 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Detects a band of approximately 110 kDa (predicted molecular weight: 88 kDa).Can be blocked with CD26 peptide (ab188121).
  • Application notes
    Is unsuitable for ICC/IF or IHC-P.
  • Target

    • Function

      Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline.
    • Tissue specificity

      Expressed specifically in lymphatic vessels but not in blood vessels in the skin, small intestine, esophagus, ovary, breast and prostate glands. Not detected in lymphatic vessels in the lung, kidney, uterus, liver and stomach (at protein level). Expressed in the poorly differentiated crypt cells of the small intestine as well as in the mature villous cells. Expressed at very low levels in the colon.
    • Sequence similarities

      Belongs to the peptidase S9B family. DPPIV subfamily.
    • Domain

      The extracellular cysteine-rich region is necessary for association with collagen, dimer formation and optimal dipeptidyl peptidase activity.
    • Post-translational
      modifications

      The soluble form (Dipeptidyl peptidase 4 soluble form also named SDPP) derives from the membrane form (Dipeptidyl peptidase 4 membrane form also named MDPP) by proteolytic processing.
      N- and O-Glycosylated.
      Phosphorylated. Mannose 6-phosphate residues in the carbohydrate moiety are necessary for interaction with IGF2R in activated T-cells. Mannose 6-phosphorylation is induced during T-cell activation.
    • Cellular localization

      Cell membrane. Apical cell membrane. Cell projection > invadopodium membrane. Cell projection > lamellipodium membrane. Cell junction. Membrane raft. Translocated to the apical membrane through the concerted action of N- and O-Glycans and its association with lipid microdomains containing cholesterol and sphingolipids. Redistributed to membrane rafts in T-cell in a interleukin-12-dependent activation. Its interaction with CAV1 is necessary for its translocation to membrane rafts. Colocalized with PTPRC in membrane rafts. Colocalized with FAP in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Colocalized with FAP on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma. Colocalized with ADA at the cell junction in lymphocyte-epithelial cell adhesion. Colocalized with IGF2R in internalized cytoplasmic vesicles adjacent to the cell surface and Secreted. Detected in the serum and the seminal fluid.
    • Information by UniProt
    • Database links

    • Alternative names

      • CD26 antigen antibody
      • ADA-binding protein antibody
      • ADABP antibody
      • ADCP 2 antibody
      • ADCP-2 antibody
      • ADCP2 antibody
      • Adenosine deaminase complexing protein 2 antibody
      • CD 26 antibody
      • CD26 antibody
      • CD26 antigen 3 antibody
      • Dipeptidyl peptidase 4 antibody
      • Dipeptidyl peptidase 4 soluble form antibody
      • Dipeptidyl peptidase IV antibody
      • Dipeptidyl peptidase IV membrane form antibody
      • Dipeptidyl peptidase IV soluble form antibody
      • Dipeptidyl peptidase, intestinal antibody
      • Dipeptidylpeptidase 4 antibody
      • Dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2) antibody
      • Dipeptidylpeptidase IV antibody
      • DPP 4 antibody
      • DPP IV antibody
      • DPP IV estoenzyme antibody
      • DPP4 antibody
      • DPP4_HUMAN antibody
      • DPPIV antibody
      • Intestinal dipeptidyl peptidase antibody
      • T cell activation antigen CD26 antibody
      • T-cell activation antigen CD26 antibody
      • TP 103 antibody
      • TP103 antibody
      see all

    Images

    • All lanes : Anti-CD26 antibody [EPR5883(2)] (ab129060) at 1/20000 dilution (purified)

      Lane 1 : HUVEC cell lysate
      Lane 2 : PC-3 cell lysate
      Lane 3 : U87-MG cell lysate
      Lane 4 : Ramos cell lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Peroxidase conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

      Predicted band size: 88 kDa
      Observed band size: 110 kDa
      why is the actual band size different from the predicted?



      Blocking buffer and concentration: 5% NFDM/TBST.

      Diluting buffer and concentration: 5% NFDM /TBST.

    • All lanes : Anti-CD26 antibody [EPR5883(2)] (ab129060) at 1/20000 dilution

      Lane 1 : Mouse brain tissue lysate
      Lane 2 : Rat brain tissue lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Peroxidase conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

      Predicted band size: 88 kDa
      Observed band size: 110 kDa why is the actual band size different from the predicted?



      Blocking buffer and concentration: 5% NFDM/TBST.

      Diluting buffer and concentration: 5% NFDM /TBST.

    • All lanes : Anti-CD26 antibody [EPR5883(2)] (ab129060) at 1/10000 dilution (unpurified)

      Lane 1 : HUVEC cell lysate
      Lane 2 : PC-3 cell lysate
      Lane 3 : U87-MG cell lysate
      Lane 4 : Ramos cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size: 88 kDa
      Observed band size: 110 kDa why is the actual band size different from the predicted?

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

    References

    This product has been referenced in:

    • Liang PI  et al. DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness. Oncotarget 8:2995-3008 (2017). Read more (PubMed: 27936466) »
    • Baumeier C  et al. Hepatic DPP4 DNA Methylation Associates With Fatty Liver. Diabetes 66:25-35 (2017). Read more (PubMed: 27999105) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A

    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (Human primary fibroblasts from skin)
    Gel Running Conditions
    Reduced Denaturing (4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 10-well, 50 µl)
    Loading amount
    12 µg
    Specification
    Human primary fibroblasts from skin
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Aug 20 2018

    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (HUVECs)
    Gel Running Conditions
    Reduced Denaturing (8% SDS-PAGE)
    Loading amount
    20 µg
    Treatment
    10 ng/ml IL-1b for 24hrs
    Specification
    HUVECs
    Blocking step
    BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Aug 23 2016

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up